{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:10:22Z","timestamp":1790244622155,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s11912-018-0665-2","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T04:56:12Z","timestamp":1519793772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Cure of Chronic Myeloid Leukemia: Are We There Yet?"],"prefix":"10.1007","volume":"20","author":[{"given":"Tapan","family":"Saikia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"issue":"1","key":"665_CR1","first-page":"1517","volume":"94","author":"RT Silver","year":"1999","unstructured":"Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for American Society of Hematology. Blood. 1999;94(1):1517\u201336.","journal-title":"Blood"},{"issue":"2","key":"665_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7326\/0003-4819-104-2-155","volume":"104","author":"ED Thomas","year":"1986","unstructured":"Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986;104(2):155\u201363. https:\/\/doi.org\/10.7326\/0003-4819-104-2-155 .","journal-title":"Ann Intern Med"},{"issue":"3","key":"665_CR3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood.V62.3.689.bloodjournal623689","volume":"62","author":"M Talpaz","year":"1983","unstructured":"Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon induced myeloid cytoreduction in chronic myelogenous leukemia. Blood. 1983;62(3):689\u201392.","journal-title":"Blood"},{"issue":"4","key":"665_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/cncr.11223","volume":"97","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97(4):1033\u201341. https:\/\/doi.org\/10.1002\/cncr.11223 .","journal-title":"Cancer"},{"issue":"1","key":"665_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1200\/JCO.2002.20.1.214","volume":"20","author":"FX Mahon","year":"2002","unstructured":"Mahon FX, Debbrel X, Cony-Makhoul P, et al. Follow up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20(1):214\u201320. https:\/\/doi.org\/10.1200\/JCO.2002.20.1.214 .","journal-title":"J Clin Oncol"},{"issue":"12","key":"665_CR6","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H. Estimation of increasing prevalence and plateau of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123\u20137. https:\/\/doi.org\/10.1002\/cncr.26679 .","journal-title":"Cancer"},{"issue":"3","key":"665_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/0971-5851.123711","volume":"34","author":"S Bansal","year":"2013","unstructured":"Bansal S, Kumar P, Parikh P. Chronic myeloid leukemia data from India. Ind J Med Ped Oncol. 2013;34(3):154\u20138. https:\/\/doi.org\/10.4103\/0971-5851.123711 .","journal-title":"Ind J Med Ped Oncol"},{"issue":"1","key":"665_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12185-008-0230-0","volume":"89","author":"WY Au","year":"2009","unstructured":"Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009;89(1):14\u201323. https:\/\/doi.org\/10.1007\/s12185-008-0230-0 .","journal-title":"Int J Hematol"},{"key":"665_CR9","first-page":"255","volume":"19","author":"L Kumar","year":"2006","unstructured":"Kumar L. Chronic myelogenous leukemia: an update. Nat Med J Ind. 2006;19:255\u201363.","journal-title":"Nat Med J Ind"},{"issue":"22","key":"665_CR10","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1182\/blood.V128.22.2380.2380","volume":"128","author":"M Delord Jr","year":"2016","unstructured":"\u2022 Delord M Jr. 100 years of chronic myeloid leukemia prevalence in France. Blood. 2016;128(22):2380. This study highlights the present and future burden of treating CML. The rising prevalence from 2\/100,000 pre-imatinib era to 50\/100,000 in coming decades will exponentially increase economic burden on individuals and society.","journal-title":"Blood"},{"issue":"22","key":"665_CR11","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","volume":"121","author":"C Abboud","year":"2013","unstructured":"\u2022 Abboud C, Berman E, Cohen A, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439\u201342. This article points out the unrealistic price of newer drugs used in cancer. This study stimulated further publications and debates on burden of cost of newly developed biological molecules.","journal-title":"Blood"},{"issue":"24","key":"665_CR12","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches of the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.66.2866 .","journal-title":"J Clin Oncol"},{"issue":"1","key":"665_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","volume":"63","author":"PJ Fialkow","year":"1977","unstructured":"Fialkow PJ, Jacobson RJ, Papayanapoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelets and monocyte\/macrophage. Am J Med. 1977;63(1):125\u201330. https:\/\/doi.org\/10.1016\/0002-9343(77)90124-3 .","journal-title":"Am J Med"},{"issue":"1","key":"665_CR14","first-page":"85","volume":"25","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25(1):85\u2013109.","journal-title":"J Natl Cancer Inst"},{"issue":"5405","key":"665_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"J Rowley","year":"1973","unstructured":"Rowley J. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine and Giemsa staining. Nature. 1973;243(5405):290\u20133. https:\/\/doi.org\/10.1038\/243290a0 .","journal-title":"Nature"},{"issue":"6022","key":"665_CR16","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/315758a0","volume":"315","author":"N Heistercamp","year":"1985","unstructured":"Heistercamp N, Storm K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph\u2019 translocation. Nature. 1985;315(6022):758\u201361. https:\/\/doi.org\/10.1038\/315758a0 .","journal-title":"Nature"},{"issue":"4944","key":"665_CR17","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by p210\/bcr\/abl gene of Philadelphia chromosome. Science. 1990;247(4944):824\u201330. https:\/\/doi.org\/10.1126\/science.2406902 .","journal-title":"Science"},{"issue":"6","key":"665_CR18","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","volume":"94","author":"T Holyoake","year":"1999","unstructured":"Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999;94(6):2056\u201364.","journal-title":"Blood"},{"issue":"24","key":"665_CR19","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.4161\/cc.5.24.3573","volume":"5","author":"DJ Barnes","year":"2006","unstructured":"Barnes DJ, Melo JV. Primitive, quiescent and difficult to kill: the role of non-proliferating cells in chronic myeloid leukemia. Cell Cycle. 2006;5(24):2862\u20136. https:\/\/doi.org\/10.4161\/cc.5.24.3573 .","journal-title":"Cell Cycle"},{"issue":"7","key":"665_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cell in blast crisis CML. N Engl J Med. 2004;351(7):657\u201367. https:\/\/doi.org\/10.1056\/NEJMoa040258 .","journal-title":"N Engl J Med"},{"issue":"6","key":"665_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ccr.2004.12.005","volume":"6","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, Weissman IL, Passegue\u2019 E. Chronic versus acute myelogenous leukemia: a question of self-renewal. Cancer Cell. 2004;6(6):531\u20133. https:\/\/doi.org\/10.1016\/j.ccr.2004.12.005 .","journal-title":"Cancer Cell"},{"issue":"12","key":"665_CR22","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"T Holyoake","year":"2017","unstructured":"\u2022\u2022 Holyoake T, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129(12):1595\u2013606. This extensive review on CML stem cells, discusses persistence of LSC despite very effective TKIs and the challenge in curing CML. There are biological pathways that escape TKIs and are responsible for resistance, relapse and progression of disease phase. https:\/\/doi.org\/10.1182\/blood-2016-09-696013 .","journal-title":"Blood"},{"key":"665_CR23","first-page":"1990","volume":"555","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;555:1990.","journal-title":"Blood"},{"key":"665_CR24","doi-asserted-by":"crossref","unstructured":"Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:2462\u20135.","DOI":"10.1182\/blood.V76.12.2462.bloodjournal76122462"},{"issue":"3","key":"665_CR25","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","volume":"91","author":"S Slavin","year":"1998","unstructured":"Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756\u201363.","journal-title":"Blood"},{"issue":"2","key":"665_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","volume":"101","author":"R Or","year":"2003","unstructured":"Or R, Shapira MA, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for treatment of chronic myeloid leukemia in first chronic phase. Blood. 2003;101(2):441\u20135. https:\/\/doi.org\/10.1182\/blood-2002-02-0535 .","journal-title":"Blood"},{"key":"665_CR27","doi-asserted-by":"crossref","unstructured":"Das M, Saikia TK, Advani SH, Parikh PM, Tawde S. Use of reduced-intensity conditioning for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant. 2003;32:125\u20139.","DOI":"10.1038\/sj.bmt.1704107"},{"issue":"9","key":"665_CR28","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","volume":"106","author":"C Crawley","year":"2005","unstructured":"Crawley C, Szyldo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;106(9):2969\u201376. https:\/\/doi.org\/10.1182\/blood-2004-09-3544 .","journal-title":"Blood"},{"issue":"9","key":"665_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/bmt.2008.218","volume":"42","author":"H Bittencourt","year":"2008","unstructured":"Bittencourt H, Funke V, Fogliatto L, Magalh\u00e3es S, Setubal D, Paz A, et al. Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplant. 2008;42(9):597\u2013600. https:\/\/doi.org\/10.1038\/bmt.2008.218 .","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"665_CR30","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","volume":"109","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007;109(11):4686\u201392. https:\/\/doi.org\/10.1182\/blood-2006-11-055186 .","journal-title":"Blood"},{"key":"665_CR31","doi-asserted-by":"crossref","unstructured":"Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood. 2013;122(6):6041\u20136051.","DOI":"10.1182\/blood-2013-05-501569"},{"issue":"s1","key":"665_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1365-2141.1991.tb08117.x","volume":"79","author":"M Talpaz","year":"1991","unstructured":"Talpaz M, Kantarjian H, Kurzrock R, Guttermann JU. Interferon alpha in the therapy of CML. Br J Haematol. 1991;79(s1):38\u201341. https:\/\/doi.org\/10.1111\/j.1365-2141.1991.tb08117.x .","journal-title":"Br J Haematol"},{"issue":"4","key":"665_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1056\/NEJM199707243370402","volume":"337","author":"F Guilhot","year":"1997","unstructured":"Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337(4):223\u20139. https:\/\/doi.org\/10.1056\/NEJM199707243370402 .","journal-title":"N Engl J Med"},{"issue":"11","key":"665_CR34","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson R, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa022457 .","journal-title":"N Engl J Med"},{"key":"665_CR35","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"3639","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peg-interferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;3639:2511\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"665_CR36","doi-asserted-by":"publisher","first-page":"e0155959","DOI":"10.1371\/journal.pone.0155959","volume":"11","author":"V Polivkova","year":"2016","unstructured":"Polivkova V, Rohon P, Klamova H, Cerna O, Divoka M, Curik N, et al. Interferon-\u03b1 revisited: individualized treatment management eased the selective pressure of tyrosine kinase inhibitors on BCR-ABL1 mutations resulting in a molecular response in high-risk CML patients. PLoS One. 2016;11(5):e0155959. https:\/\/doi.org\/10.1371\/journal.pone.0155959 .","journal-title":"PLoS One"},{"issue":"1","key":"665_CR37","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger E, Zimmermann J, Mett H, Meyer T, M\u00fcller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56(1):100\u20134.","journal-title":"Cancer Res"},{"issue":"5","key":"665_CR38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of selective inhibitor of Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561\u20136. https:\/\/doi.org\/10.1038\/nm0596-561 .","journal-title":"Nat Med"},{"issue":"7","key":"665_CR39","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ. The development of imatinib as therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7):2640\u201353. https:\/\/doi.org\/10.1182\/blood-2004-08-3097 .","journal-title":"Blood"},{"issue":"14","key":"665_CR40","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031\u20137. https:\/\/doi.org\/10.1056\/NEJM200104053441401 .","journal-title":"N Engl J Med"},{"issue":"23","key":"665_CR41","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317. https:\/\/doi.org\/10.1056\/NEJMoa062867 .","journal-title":"N Engl J Med"},{"key":"665_CR42","doi-asserted-by":"crossref","unstructured":"Hochhaus A. O\u2019Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054\u20131061.","DOI":"10.1038\/leu.2009.38"},{"issue":"10","key":"665_CR43","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson R, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1609324 .","journal-title":"N Engl J Med"},{"issue":"24","key":"665_CR44","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisiil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139. https:\/\/doi.org\/10.1056\/NEJMoa0912614 .","journal-title":"N Engl J Med"},{"key":"665_CR45","first-page":"1044","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"\u2022\u2022 Hochhaus A, Sagloi G, Hughes TP, et al. Long-term benefit and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. N Engl J Med. 2016;30:1044\u201354. This latest analysis of long-term survival of CML-CP receiving imatinib proves the utility, with more than 80% long-term survival at 10-year median follow-up.","journal-title":"N Engl J Med"},{"issue":"24","key":"665_CR46","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260\u201370. https:\/\/doi.org\/10.1056\/NEJMoa1002315 .","journal-title":"N Engl J Med"},{"issue":"20","key":"665_CR47","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340. https:\/\/doi.org\/10.1200\/JCO.2015.64.8899 .","journal-title":"J Clin Oncol"},{"issue":"6","key":"665_CR48","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1634\/theoncologist.2010-0388","volume":"16","author":"S Soverini","year":"2011","unstructured":"Soverini S, Rosti G, Iacobucci I, Baccarani M, Martinelli G. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC50? Oncologist. 2011;16(6):868\u201376. https:\/\/doi.org\/10.1634\/theoncologist.2010-0388 .","journal-title":"Oncologist"},{"issue":"28","key":"665_CR49","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Br\u00fcmmendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486\u201392. https:\/\/doi.org\/10.1200\/JCO.2011.38.7522 .","journal-title":"J Clin Oncol"},{"issue":"5","key":"665_CR50","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresier A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukemia: an international, randomized, open label, phase 3 trial. Lancet Oncol. 2016;17(5):612\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(16)00080-2 .","journal-title":"Lancet Oncol"},{"key":"665_CR51","unstructured":"Cortes JE, Pinilla-Ibarz J, Le Coutre PD, et al. 4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia. J Clin Oncol. 2016(suppl), abstr, 7013."},{"issue":"11","key":"665_CR52","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Guilhot RD, Guilhot F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib (STM) trial. Lancet Oncol. 2010;11(11):1029\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(10)70233-3 .","journal-title":"Lancet Oncol"},{"issue":"3","key":"665_CR53","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2016","unstructured":"\u2022\u2022 Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the French Stop Imatinib (STM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2016;35(3):298\u2013305. https:\/\/doi.org\/10.1200\/JCO.2016.68.2914 . This study is 77-month median follow-up of 100 patients who stopped imatinib. The median molecular leukemia recurrence-free survival (MRFS) was 43% at 6\u00a0months and 38% at 60\u00a0months. Restarting treatment could bring about second undetectable MRD in 55 of 61 patients within a median of 4\u00a0months.","journal-title":"J Clin Oncol"},{"issue":"4","key":"665_CR54","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):525\u20132.","journal-title":"Blood"},{"key":"665_CR55","unstructured":"\u2022\u2022 Mahon FX. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial. Blood. 2016;128:787. This largest study of stop TKI presented in December ASH 2016 Meeting included 750 patients (out of 821 included) on imatinib, nilotinib, and dasatinib had molecular data for estimation of MRFS. Three hundred forty-eight lost MMR; MRFS was 62% at 6\u00a0months, 56% at 12\u00a0months, and 52% at 24\u00a0months. Inclusion criteria needed deep molecular (DMR, BCR-ABL level 0.01% on International Scale) for the duration of at least 1\u00a0year; molecular relapse was defined by the loss of major molecular response (MMR, BCR-ABL level <\u20090.1% IS) at any one point. Longer imatinib therapy (optimal\u20135.8\u00a0years) prior to TKI-stop was associated with higher probability of MRFS."},{"key":"665_CR56","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol;2014;32(5):424\u201330. https:\/\/doi.org\/10.1200\/JCO.2012.48.5797 . This study included 80 patients on imatinib who were on prolonged imatinib therapy (median 79\u00a0months, range 30\u2013145\u00a0months) and median CMR of 41\u00a0months (24\u201396\u00a0months). The deviation from the earlier studies (STIM and TWISTER) was resumption of a TKI after loss of major molecular response (MMR), rather than any increase in BCR-ABL level. With a median follow-up of 31\u00a0months (8\u201392\u00a0months) discontinuation of imatinib, 29 (36%) patients lost MMR after a median of 4\u00a0months (2\u201317 months) and cumulative loss of MR was 35% at 12\u00a0months and 36% at 24\u00a0months., whereas losing CMR was higher. Treatment-free remission (TFR) was estimated as 64% at 12 and 24\u00a0months and 61% at 36\u00a0months. The median time to second CMR estimated as 7.3\u00a0months on re-treatment.","DOI":"10.1200\/JCO.2012.48.5797"},{"key":"665_CR57","doi-asserted-by":"crossref","unstructured":"Clarke RE, Polydoros F, Apperley KF et al. Chronic myeloid leukemia patients with stable molecular responses (at least DMR) may safely decrease the dose of their tyrosine kinase inhibitor: Data from the British Destiny Study. 2016. ASH Annual Meeting. Abstract 938.","DOI":"10.1182\/blood.V128.22.938.938"},{"key":"665_CR58","doi-asserted-by":"publisher","unstructured":"Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017;8 https:\/\/doi.org\/10.3389\/fimmu.2017.00469 .","DOI":"10.3389\/fimmu.2017.00469"},{"key":"665_CR59","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/asheducation-2011.1.136","volume":"2011","author":"JV Melo","year":"2011","unstructured":"Melo JV, Ross DM. Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? Hematology Am Soc Hematol Program. 2011;2011:136\u201342.","journal-title":"Hematology Am Soc Hematol Program"},{"key":"665_CR60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"106","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;106:28\u201337.","journal-title":"Blood"},{"issue":"5","key":"665_CR61","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NCP Cross","year":"2015","unstructured":"\u2022\u2022 Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29(5):999\u20131003. https:\/\/doi.org\/10.1038\/leu.2015.29 . This important study describes the methodology for accurate definition of deep molecular responses for optimal management and comparison of independent data sets, developed as a part of the European Treatment and Outcome Study for CML (EUTOS).","journal-title":"Leukemia"},{"issue":"7046","key":"665_CR62","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukemia. Nature. 2005;435(7046):1267\u201370. https:\/\/doi.org\/10.1038\/nature03669 .","journal-title":"Nature"},{"issue":"6","key":"665_CR63","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","volume":"118","author":"M Tang","year":"2011","unstructured":"Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemia stem cells. Blood. 2011;118(6):1622\u201331. https:\/\/doi.org\/10.1182\/blood-2011-02-339267 .","journal-title":"Blood"},{"issue":"10","key":"665_CR64","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I Roeder","year":"2002","unstructured":"Roeder I, Glauche HM, Hochhaus A, et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med. 2002;12(10):1181\u20134.","journal-title":"Nat Med"},{"issue":"6","key":"665_CR65","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3324\/haematol.2009.015271","volume":"95","author":"T Lenaerts","year":"2010","unstructured":"Lenaerts T, Pacheo JM, Traulsen A, Dingly D. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica. 2010;95(6):900\u20137. https:\/\/doi.org\/10.3324\/haematol.2009.015271 .","journal-title":"Haematologica"},{"issue":"20","key":"665_CR66","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","volume":"118","author":"R Bhatia","year":"2003","unstructured":"Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;118(20):4701\u20137.","journal-title":"Blood"},{"issue":"13","key":"665_CR67","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","volume":"118","author":"JC Chomel","year":"2011","unstructured":"Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118(13):3657\u201360. https:\/\/doi.org\/10.1182\/blood-2011-02-335497 .","journal-title":"Blood"},{"issue":"6","key":"665_CR68","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Scheminek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501\u201310. https:\/\/doi.org\/10.1182\/blood-2010-12-326843 .","journal-title":"Blood"},{"issue":"11\u201312","key":"665_CR69","doi-asserted-by":"publisher","first-page":"313","DOI":"10.18632\/oncoscience.327","volume":"3","author":"BZ Carter","year":"2016","unstructured":"Carter BZ, Andreeff M. Eradication of CML stem cells. Oncoscience. 2016;3(11\u201312):313\u20135. https:\/\/doi.org\/10.18632\/oncoscience.327 .","journal-title":"Oncoscience"},{"issue":"10","key":"665_CR70","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/leu.2017.87","volume":"31","author":"H Zhou","year":"2017","unstructured":"Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, et al. Combined inhibition of \u03b2-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017;31(10):2065\u201374. https:\/\/doi.org\/10.1038\/leu.2017.87 .","journal-title":"Leukemia"},{"issue":"10","key":"665_CR71","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1056\/NEJMe1700833","volume":"376","author":"D Longo","year":"2017","unstructured":"Longo D. Imatinib changed everything. N Engl J Med. 2017;376(10):982\u20133. https:\/\/doi.org\/10.1056\/NEJMe1700833 .","journal-title":"N Engl J Med"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-018-0665-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-018-0665-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-018-0665-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T20:22:55Z","timestamp":1603916575000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-018-0665-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1007\/s11912-018-0665-2","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"28 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Tapan Saikia declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"12"}}